255 related articles for article (PubMed ID: 22000822)
1. Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex.
Perek-Polnik M; Jóźwiak S; Jurkiewicz E; Perek D; Kotulska K
Eur J Paediatr Neurol; 2012 Jan; 16(1):83-5. PubMed ID: 22000822
[TBL] [Abstract][Full Text] [Related]
2. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex.
Goyer I; Dahdah N; Major P
Pediatr Neurol; 2015 Apr; 52(4):450-3. PubMed ID: 25682485
[TBL] [Abstract][Full Text] [Related]
3. Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex.
Fukumura S; Watanabe T; Takayama R; Minagawa K; Tsutsumi H
J Child Neurol; 2015 Aug; 30(9):1192-5. PubMed ID: 25143481
[TBL] [Abstract][Full Text] [Related]
4. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
[TBL] [Abstract][Full Text] [Related]
7. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
Krueger DA; Care MM; Holland K; Agricola K; Tudor C; Mangeshkar P; Wilson KA; Byars A; Sahmoud T; Franz DN
N Engl J Med; 2010 Nov; 363(19):1801-11. PubMed ID: 21047224
[TBL] [Abstract][Full Text] [Related]
8. Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report.
Wiemer-Kruel A; Woerle H; Strobl K; Bast T
Neuropediatrics; 2014 Apr; 45(2):129-31. PubMed ID: 24293099
[TBL] [Abstract][Full Text] [Related]
9. [Oligosymptomatic variant of tuberous sclerosis with subependymal giant cell astrocytoma].
Rieger E; Binder B; Starz I; Oberbauer R; Urban C
Padiatr Padol; 1991; 26(1):35-7. PubMed ID: 2057209
[TBL] [Abstract][Full Text] [Related]
10. Everolimus (RAD001): first systemic treatment for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Józwiak S; Stein K; Kotulska K
Future Oncol; 2012 Dec; 8(12):1515-23. PubMed ID: 23231513
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
[TBL] [Abstract][Full Text] [Related]
12. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?
Wiegand G; May TW; Ostertag P; Boor R; Stephani U; Franz DN
Eur J Paediatr Neurol; 2013 Nov; 17(6):631-8. PubMed ID: 23845174
[TBL] [Abstract][Full Text] [Related]
13. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
Cheng S; Hawkins C; Taylor MD; Bartels U
Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
[TBL] [Abstract][Full Text] [Related]
14. Response of subependymal giant cell astrocytoma with spinal cord metastasis to everolimus.
Aguilera D; Flamini R; Mazewski C; Schniederjan M; Hayes L; Boydston W; Castellino RC; MacDonald TJ
J Pediatr Hematol Oncol; 2014 Oct; 36(7):e448-51. PubMed ID: 24276039
[TBL] [Abstract][Full Text] [Related]
15. [Oligosymptomatic Bourneville-Pringle tuberous sclerosis of the brain with giant cell astrocytoma].
Rieger E; Starz I; Binder B; Oberbauer R; Urban C
Hautarzt; 1991 Oct; 42(10):638-41. PubMed ID: 1757257
[TBL] [Abstract][Full Text] [Related]
16. [Tuberous sclerosis with intraventricular tumor: report of 2 cases].
Fukuoka H; Takagi T; Shimazu N; Nagai H
No Shinkei Geka; 1986 Oct; 14(11):1377-81. PubMed ID: 3808199
[TBL] [Abstract][Full Text] [Related]
17. Everolimus tablets for patients with subependymal giant cell astrocytoma.
Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
[TBL] [Abstract][Full Text] [Related]
18. [A case of subependymal giant cell astrocytoma not associated with tuberous sclerosis].
Watanabe Y; Oki S; Migita K; Isobe N; Okazaki T; Nabika S
No Shinkei Geka; 2003 May; 31(5):543-8. PubMed ID: 12755028
[TBL] [Abstract][Full Text] [Related]
19. Persistent communicating hydrocephalus in adult tuberous sclerosis patients: a possible therapeutic role for everolimus.
Laviv Y; Jackson S; Rappaport ZH
Acta Neurochir (Wien); 2015 Feb; 157(2):241-5. PubMed ID: 25524658
[TBL] [Abstract][Full Text] [Related]
20. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.
Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S
Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
